Top10%閲覧論文に選ばれたようです。
Full text views:3744
Citations: 14...2025年に出版され、8ヶ月 (0.666年)で14 citesなので、この論文の瞬間最大IFは21点!(笑)
Comparison of ABI, ENZ, APA for mHSPC: A multicenter study - Yanagisawa T- 2025 - The Prostate https://t.co/IywIPiFY2A
📈Our systematic review and meta-analysis on prognostic factors of PSMA-targeted radioligand therapy in mCRPC is now featured on @UroToday's "Beyond the Abstract".
We discussed the key predictors for treatment outcomes. Check it out here:
https://t.co/JSxfgaJqB1
#mCRPC#PSMA
34th Malaysian Urological Conference:
MUC2025
Dr. Yanagisawa was invited and spoke at the Plenary session about En-bloc TUR-BT
and Dr. Enei gave a presentation about PSMA-RLT for the best poster competition
@gehi87@Enenny_SS@MyUrologyAssoc
JSES IllustCon 17
📌Robot-Assisted Radical Nephrectomy and IVC Thrombectomy
📝The distal IVC was stapled and transected. IVC was cranially clamped and the Pringle maneuver was also performed. Then the tumor was directly identified and resected with IVC. These procedures are illustrated in a single figure.
🖊Dr.Cazz
#JSESイラストコンテスト #JSES_illustration_contest
Radical cystectomy (RC) and trimodality therapy (TMT) yield comparable outcomes in muscle-invasive bladder cancer (MIBC)?
✨ 74.4% complete response with TMT.
🔄 23.1% recurrence rate in TMT-treated patients.
⚠️ 11.4% grade ≥3 toxicity for TMT.
Does this change your practice?
Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis by Akihiro Matsukawa et al
https://t.co/xcIgyxDRtZ
#UroSoMe#MedTwitter#EUO#PCa#ProstateCancer
@gehi87 from @jikei_urology talking about SR, MA & NMA! Dr Takafumi Yanagisawa is such a hardworking and talented researcher. Thank you for sharing with us your valuable experiences! #UroSoMe
Recent advances in managing biochemical recurrence (BCR) after local treatment for prostate cancer (PCa) 🎯
📊 We analyzed 19 studies (9117 patients) to compare different salvage therapies post-radical prostatectomy (RP) or radiation therapy (RT). Results show that combining RT with hormone therapy offers significant improvements in metastatic-free survival (MFS)! 🌟
🔍 Key findings:
- RT + hormone therapy = ⬆️ MFS
- Best RT-based strategy: Prostate bed RT + elective nodal RT + ADT
- Top hormone-based strategy: Enzalutamide + ADT for MFS & OS
🧬 For high-risk BCR or post-RT recurrence, consider adding ARSI (androgen receptor signaling inhibitors) to ADT.
🚑 These combinations represent the next step in PCa care, ensuring better outcomes for patients!
https://t.co/cIr7zrZLlV
#ProstateCancer #CancerResearch #urooncology #BCR #AndrogenTherapy #RadicalProstatectomy #RadiationTherapy #CancerTreatment
@ZilliThomas@joniau
1st Int'l Urologic Cancer Symposium: Renowned urologists from 3 countries gave informative talks. Great dinner followed, joined by Dr. Teoh & Dr. Leung.
Join us for the 1st Int'l Urologic Cancer Symposium in Tokyo!
8/28, 18:30-20:30 Jikei Uni.
Featuring @dr_rajwa, @BenjaminPradere & @FQuhal. Open to all, including non-institution members!
The EB-StaR study was published at European Urology today! ✅ It is a randomised study comparing en bloc resection of bladder tumour (ERBT) and conventional transurethral resection of bladder tumour (TURBT) in patients with bladder tumour(s) <= 3 cm in size. 🏥 #UroSoMe (1/n)